Vinva Investment Management Ltd Sells 5,294 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Vinva Investment Management Ltd trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 15.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,609 shares of the biotechnology company’s stock after selling 5,294 shares during the quarter. Vinva Investment Management Ltd’s holdings in United Therapeutics were worth $10,616,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. ClariVest Asset Management LLC boosted its position in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the second quarter valued at $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the second quarter worth $33,000. USA Financial Formulas bought a new stake in shares of United Therapeutics in the third quarter worth $33,000. Finally, Brooklyn Investment Group acquired a new stake in United Therapeutics in the third quarter valued at $33,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 127,227 shares of company stock worth $47,398,820. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 0.3 %

Shares of UTHR opened at $378.13 on Thursday. The business’s fifty day moving average is $366.18 and its 200 day moving average is $333.84. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The stock has a market cap of $16.88 billion, a P/E ratio of 16.61, a P/E/G ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. The business’s revenue was up 22.9% on a year-over-year basis. On average, analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Bank of America lowered their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group upped their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.